Germany, FranceGermany

Sartorius Stedim Biotech rocks single-use bioreactor market

14.05.2009

Aubagne/Frankfurt – Sartorius Stedim Biotech SA has substantially expanded its technology portfolio as a supplier for the bio-pharmaceutical industry. At the ACHEMA, the world´s largest trade fair for bioprocess equipment, the company presented two new prototypes of single-use bioreactors that make use of novel mixing technologies co-developed with Bayer Technology Services GmbH (BTS) and Swiss ExcellGene SA. The disposable systems are a major driver of growth for suppliers of the biopharmaceutical industry, because they offer cheaper and more flexible production possibilties than stainless steel fermentors that need time-consuming and expensive cleaning validation.
With the new bioreactors, which are specially designed for the manufacture of monoclonal antibodies, recombinant proteins and vaccines, Sartorius attacks competitors like Thermo Fisher, who offer single use stirred bioreactors or GE Healthcare, who markets shaked reusable plastic bags for mid-scale biomanufacture.
„Based on this comprehensive technology platform, we are taking a huge step forward towards achieving our goal of becoming the global market leader in single-use bioreactors," said Dr. Oscar-Werner Reif, Member of Sartorius Stedim Biotech's Board of Directors.
From 2010, the company plans to extend its technology portfolio, which already comprises stirred and shaked bioreactor types, by the novel systems. The rotationally oscillating bioreactor, co-developed with Bayer Schering Pharma AG, allows for surface or membrane gasing of sensitive cultures. The orbital shake bioreactor, developed with ExcellGene, allows for screening of media and cultivation conditions. Each of the four agitation technologies offers user specific advantages contingent upon the cells to be produced, the scale-up level of the cell cultures and additional process parameters. Despite financial crisis, ACHEMA achieved its second best result ever, regarding the number of exhibitors.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/sartorius-stedim-biotech-rocks-single-use-bioreactor-market.html

Product of the week

Products

Events

All Events

Current issue

All issues